Emcure Pharmaceuticals Share Price Surges After Board Approves Merger of Two Wholly Owned Subsidiaries

Emcure Pharmaceuticals has approved a proposal to merge its two wholly owned subsidiaries, Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, into the parent company, as per the exchange filing. 

The board approved the draft Composite Scheme of Amalgamation at its meeting on October 12, 2026. Emcure said the plan is intended to simplify the group structure and improve operational efficiency. 

Zuventus Reports Turnover of ₹1,040 Crore 

Zuventus Healthcare recorded turnover of ₹1,040.58 crore in FY 2025-26, with a net worth of ₹871.46 crore as of March 31, 2026. 

Emcutix Biopharmaceuticals reported turnover of ₹29.37 crore during the same financial year. Its net worth stood at negative ₹13.07 crore at the end of March 2026. 

No Cash Payment or New Shares Planned 

Emcure will not pay any consideration for the merger, as it already owns the entire share capital of both subsidiaries. The scheme also does not provide for the issuance of new shares by the parent company. 

As a result, the company stated that its shareholding pattern will remain unchanged following the amalgamation. 

Emcure Reports ₹5,243 Crore Turnover 

Emcure Pharmaceuticals recorded turnover of ₹5,243.19 crore in FY 2025-26, while its net worth stood at ₹3,710.60 crore as of March 31, 2026. 

The proposed merger brings the two subsidiary businesses under the parent company, with operational efficiency and group-level rationalisation cited as the objectives. 

Read More: Power Grid Share Price in Focus After Commissioning Rajasthan Transmission Project! 

Emcure Pharmaceuticals Share Price Performance  

As of 12 October 2026, at 2:13 PM, Emcure Pharmaceuticals Ltd share price is trading at ₹1,862.80 per share, reflecting a surge of 1.60% from the previous trading session. 

Conclusion 

Emcure's board has approved the draft merger scheme, with no cash consideration or new share issuance planned. The proposal remains subject to the required approvals before the amalgamation can proceed. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.